Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 3/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.42 |
| ▸ | FPR2 | P25090 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697264 | 0.89 | SLC5A1 (0.41) | SLC5A1SLC5A2FPR2NPC1RAB9A | |
| SCHEMBL16697947 | 0.88 | CYP26A1 (0.42) | KMT2AMEN1CYP19A1 | |
| SCHEMBL16697479 | 0.86 | CCR1 (0.47) | KMT2AMEN1HSP90AA1 | |
| SCHEMBL16697439 | 0.86 | POLB (0.41) | SLC5A1SLC5A2NPC1RAB9AKMT2A | |
| SCHEMBL16697897 | 0.85 | HTT (0.41) | SLC5A1SLC5A2FPR2NPC1RAB9A | |
| SCHEMBL16697685 | 0.83 | LPAR1 (0.39) | SLC5A1SLC5A2NPC1RAB9AKMT2A | |
| SCHEMBL16698165 | 0.83 | PIN1 (0.42) | SLC5A1SLC5A2 | |
| SCHEMBL16697375 | 0.81 | KMT2A (0.37) | FPR2KMT2AMEN1 | |
| SCHEMBL16697230 | 0.80 | FPR2 (0.40) | FPR2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL16699810 | 0.77 | LPAR1 (0.47) | FPR2NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | SLC5A1 2682/4885SLC5A2 3005/4885FPR2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.